Arvinas Stock Earnings Reports

Arvinas reported Q1 2026 results and highlighted several strategic and clinical milestones. The company celebrated the FDA approval of VEPPANU (vepdegestrant), the first heterobifunctional PROTAC degrader approved, and announced a global commercialization, development and manufacturing out-license with Rigel Pharmaceuticals (Pfizer and Arvinas to split economics 50/50). This out-license frees Arvinas to focus capital on its pipeline while Rigel will leverage its commercial infrastructure to bring VEPPANU to patients. Arvinas is advancing four Phase 1 clinical programs (ARV-102 for LRRK2 in neurodegeneration, ARV-806 KRAS G12D degrader, ARV-393 BCL6 degrader in lymphomas, and ARV-027 for SBMA) and expects multiple clinical updates later in 2026. Key clinical details: ARV-102 demonstrated ~50%+ CSF LRRK2 reductions and downstream biomarker modulation with good tolerability in PD patients; the U.S. Phase 1b in PSP is on clinical hold pending final chronic nonhuman primate tox data expected mid-2026, with EU trials unaffected and global Phase 2 planning unchanged. ARV-806 completed dose-escalation enrollment early, with initial monotherapy safety/PK/PD and response data expected later in 2026 and planned expansion cohorts (including PDAC). ARV-393 has shown early responses in B- and T-cell lymphomas and has initiated a combination trial with glofitamab. ARV-027 (SBMA) has completed early healthy volunteer cohorts; preclinical muscle-targeted degradation showed functional benefit. Financially, Q1 revenue fell versus year-ago due to changes in Pfizer collaboration revenue recognition; R&D and G&A expenses have materially declined following cost reductions. Cash on hand was $614.9M, with cash runway guidance into H2 2028 and anticipated milestone/cash inflows related to VEPPANU/Rigel deal.